• Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

In-Situ Malignant Melanoma In A Mole that Changed Appearance


A biopsy is the only way to determine if this is a primary cutaneous neoplasm or a cutaneous metastasis from a visceral carcinoma.

A 63-year-old man presented for medical attention for a slowly growing, 8-cm skin lesion on the back. The oozing mass was slightly tender and often bled spontaneously.

Key point: This appears to be a tumor. The size and history of bleeding suggest a malignancy. There is no way to know if this is a primary cutaneous neoplasm (basal cell or squamous cell carcinoma, soft tissue sarcoma, malignant melanoma) or a cutaneous metastasis from visceral carcinoma without performing a biopsy. Aside from routine histology, tumor markers and gene mutations may be important in determining optimal therapy. A biopsy disclosed malignant melanoma. A systemic workup revealed widespread, multi-organ metastatic disease.

Treatment: The primary cutaneous lesion was excised. Because of the presence of the V600E B-raf mutation, vemurafenib chemotherapy was started, and the patient responded well.

Note: New, targeted therapies offer hope of prolonged progression-free survival-and even cure-in situations in which the prognosis was previously quite grim.

Related Content
© 2024 MJH Life Sciences

All rights reserved.